Iron Triangle Partners LP Has $27.91 Million Holdings in Tenet Healthcare Corporation $THC

Iron Triangle Partners LP reduced its position in shares of Tenet Healthcare Corporation (NYSE:THC) by 27.7% in the third quarter, HoldingsChannel reports. The firm owned 137,448 shares of the company’s stock after selling 52,552 shares during the quarter. Tenet Healthcare makes up 4.0% of Iron Triangle Partners LP’s investment portfolio, making the stock its 10th largest position. Iron Triangle Partners LP’s holdings in Tenet Healthcare were worth $27,907,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Norges Bank purchased a new position in shares of Tenet Healthcare during the 2nd quarter worth $206,981,000. Eminence Capital LP purchased a new position in Tenet Healthcare during the third quarter valued at $225,263,000. Boston Partners grew its holdings in Tenet Healthcare by 95.0% during the second quarter. Boston Partners now owns 2,267,142 shares of the company’s stock valued at $398,949,000 after purchasing an additional 1,104,500 shares during the period. AQR Capital Management LLC increased its position in Tenet Healthcare by 62.3% in the third quarter. AQR Capital Management LLC now owns 1,876,423 shares of the company’s stock worth $380,989,000 after buying an additional 720,160 shares in the last quarter. Finally, Alliancebernstein L.P. raised its stake in shares of Tenet Healthcare by 375.7% in the second quarter. Alliancebernstein L.P. now owns 790,254 shares of the company’s stock worth $139,085,000 after buying an additional 624,125 shares during the period. 95.44% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Paola M. Arbour sold 6,500 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $238.43, for a total value of $1,549,795.00. Following the completion of the sale, the executive vice president owned 29,291 shares in the company, valued at approximately $6,983,853.13. This trade represents a 18.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Thomas W. Arnst sold 8,000 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $238.85, for a total transaction of $1,910,800.00. Following the transaction, the executive vice president owned 12 shares in the company, valued at $2,866.20. The trade was a 99.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 46,517 shares of company stock valued at $10,943,111. 0.81% of the stock is currently owned by company insiders.

Analyst Ratings Changes

THC has been the subject of several analyst reports. Royal Bank Of Canada increased their target price on shares of Tenet Healthcare from $253.00 to $277.00 and gave the stock an “outperform” rating in a report on Thursday, February 12th. UBS Group increased their price objective on shares of Tenet Healthcare from $260.00 to $288.00 and gave the stock a “buy” rating in a research note on Thursday, February 12th. Leerink Partners raised their price objective on shares of Tenet Healthcare from $255.00 to $264.00 and gave the company an “outperform” rating in a research report on Friday, February 20th. Weiss Ratings raised shares of Tenet Healthcare from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, December 29th. Finally, Morgan Stanley restated an “overweight” rating and issued a $260.00 price objective on shares of Tenet Healthcare in a research report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $250.56.

Tenet Healthcare Stock Up 1.4%

Shares of NYSE THC opened at $227.79 on Monday. The stock has a market capitalization of $19.81 billion, a price-to-earnings ratio of 14.71, a P/E/G ratio of 1.10 and a beta of 1.39. The company has a current ratio of 1.76, a quick ratio of 1.68 and a debt-to-equity ratio of 2.18. The firm’s 50-day moving average price is $213.46 and its 200-day moving average price is $204.31. Tenet Healthcare Corporation has a 12-month low of $109.82 and a 12-month high of $247.21.

Tenet Healthcare (NYSE:THC) last released its earnings results on Wednesday, February 11th. The company reported $4.70 earnings per share for the quarter, beating the consensus estimate of $4.08 by $0.62. The firm had revenue of $5.53 billion for the quarter, compared to the consensus estimate of $5.47 billion. Tenet Healthcare had a return on equity of 26.33% and a net margin of 6.60%.The company’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.44 EPS. Tenet Healthcare has set its FY 2026 guidance at 16.190-18.470 EPS. On average, equities research analysts anticipate that Tenet Healthcare Corporation will post 12.24 EPS for the current fiscal year.

Tenet Healthcare Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.